United Therapeutics Corp

Market Summary

USD241.65-0.42

Market Closed

-0.17%

UTHR Alerts

1 major insider sales recently.

UTHR Stock Price

View Fullscreen

UTHR RSI Chart

UTHR Alerts

1 major insider sales recently.

UTHR Valuation

Market Cap

11.4B

Price/Earnings (Trailing)

12.64

Price/Sales (Trailing)

5.16

EV/EBITDA

8.1

Price/Free Cashflow

14.88

UTHR Price/Sales (Trailing)

UTHR Profitability

EBT Margin

52.98%

Return on Equity

16.11%

Return on Assets

13.04%

Free Cashflow Yield

6.72%

UTHR Fundamentals

UTHR Revenue

Revenue (TTM)

2.2B

Revenue Y/Y

18.1%

Revenue Q/Q

2.16%

UTHR Earnings

Earnings (TTM)

899.8M

Earnings Y/Y

11.83%

Earnings Q/Q

3.24%

Price Action

52 Week Range

204.44283.09

(Low)(High)

Last 7 days

0.9%

Last 30 days

5.1%

Last 90 days

7.5%

Trailing 12 Months

-12.6%

How does UTHR drawdown profile look like?

UTHR Financial Health

Current Ratio

8.68

UTHR Investor Care

Shares Dilution (1Y)

3.11%

Diluted EPS (TTM)

18.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	2.0B	2.1B	2.2B	0
2022	1.8B	1.8B	1.9B	1.9B
2021	1.5B	1.6B	1.7B	1.7B
2020	1.4B	1.4B	1.4B	1.5B
2019	1.6B	1.5B	1.5B	1.4B
2018	1.7B	1.7B	1.7B	1.6B
2017	1.6B	1.6B	1.7B	1.7B
2016	1.5B	1.6B	1.6B	1.6B
2015	1.3B	1.3B	1.4B	1.5B
2014	1.2B	1.2B	1.2B	1.3B
2013	957.0M	1.0B	1.1B	1.1B
2012	784.9M	826.7M	867.4M	916.1M
2011	629.5M	678.5M	711.7M	743.2M
2010	405.1M	455.8M	527.2M	592.9M
2009	0	335.9M	362.4M	358.9M
2008	0	0	0	281.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for UTHR

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 01, 2023	giltner richard	back to issuer	-1,203,650	240	-5,000	-
Dec 01, 2023	giltner richard	acquired	440,150	88.03	5,000	-
Nov 29, 2023	olian judy d.	gifted	-	-	-950	-
Nov 16, 2023	mahon paul a	acquired	706,560	117	6,000	evp & general counsel
Nov 16, 2023	mahon paul a	sold	-1,359,590	226	-6,000	evp & general counsel
Nov 07, 2023	patusky christopher	acquired	176,060	88.03	2,000	-
Nov 07, 2023	patusky christopher	back to issuer	-460,880	230	-2,000	-
Nov 02, 2023	mahon paul a	acquired	706,560	117	6,000	evp & general counsel
Nov 02, 2023	mahon paul a	sold	-1,354,550	225	-6,000	evp & general counsel
Oct 19, 2023	mahon paul a	acquired	706,560	117	6,000	evp & general counsel

Which funds bought or sold UTHR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Dec 06, 2023	CITIGROUP INC	added	15.27	2,814,440	18,497,800	0.01%
Dec 01, 2023	B. Riley Wealth Advisors, Inc.	new	-	218,642	218,642	0.01%
Nov 27, 2023	USA FINANCIAL FORMULAS	unchanged	-	1,162	51,272	0.08%
Nov 27, 2023	TRUST CO OF VERMONT	new	-	10,616	10,616	-%
Nov 24, 2023	DEUTSCHE BANK AG\	reduced	-71.61	-33,101,800	13,552,400	0.01%
Nov 22, 2023	Graham Capital Management, L.P.	new	-	405,888	405,888	0.01%
Nov 22, 2023	KBC Group NV	unchanged	-	-	181,000	-%
Nov 22, 2023	Public Sector Pension Investment Board	unchanged	-	40,960	1,806,960	0.01%
Nov 21, 2023	COMERICA BANK	added	2,697	35,366,200	35,368,200	0.18%
Nov 17, 2023	Diversified Trust Co	new	-	286,403	286,403	0.01%

Latest Funds Activity

Are funds buying UTHR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own UTHR

No. of Funds

Schedule 13G FIlings of United Therapeutics Corp

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jul 10, 2023	wellington management group llp	10.01%	4,688,824	SC 13G/A
Mar 08, 2023	blackrock inc.	10.2%	4,726,986	SC 13G/A
Feb 14, 2023	avoro capital advisors llc	6.3%	2,865,000	SC 13G/A
Feb 13, 2023	renaissance technologies llc	5.14%	2,344,492	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.83%	4,480,719	SC 13G/A
Feb 06, 2023	wellington management group llp	5.64%	2,569,263	SC 13G
Feb 02, 2023	rothblatt martine a	8.0%	3,919,603	SC 13G/A
Jan 24, 2023	blackrock inc.	9.9%	4,510,211	SC 13G/A
Feb 11, 2022	renaissance technologies llc	6.48%	2,917,191	SC 13G/A

Recent SEC filings of United Therapeutics Corp

View All Filings

Date Filed	Form Type	Document
Dec 07, 2023	144	Notice of Insider Sale Intent
Dec 07, 2023	4	Insider Trading
Dec 04, 2023	4	Insider Trading
Dec 04, 2023	SC TO-T/A	SC TO-T/A
Dec 01, 2023	4	Insider Trading
Nov 29, 2023	8-K	Current Report
Nov 17, 2023	4	Insider Trading
Nov 16, 2023	144	Notice of Insider Sale Intent
Nov 13, 2023	SC TO-T	SC TO-T
Nov 08, 2023	4	Insider Trading

UTHR Fair Value

Peers (Alternatives to United Therapeutics Corp)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
HILS	30.9B	-	5.25%	401813.88%	-3.6K	218.4K	-	-102.45%
MRNA	30.5B	10.7B	8.54%	-55.34%	-8.79	2.86	-53.67%	-129.46%
ALNY	22.2B	1.7B	4.15%	-23.37%	-43.62	12.9	79.37%	56.87%
BMRN	17.9B	2.3B	11.05%	-8.44%	121.62	7.74	15.05%	75.21%
INCY	12.4B	3.6B	0.84%	-34.33%	29.1	3.43	8.35%	-51.49%
MID-CAP
APLS	7.6B	272.9M	35.37%	34.74%	-12.51	27.78	141.38%	4.43%
BBIO	5.9B	-	14.36%	263.35%	-10.02	48.33	54.84%	-12.96%
ACAD	3.6B	631.9M	-7.32%	48.57%	-24.01	5.65	23.54%	31.53%
AXSM	3.3B	223.4M	11.28%	-10.13%	-16.47	14.87	-	-26.24%
ARWR	2.6B	240.7M	-10.83%	-25.35%	-12.82	10.93	-1.03%	-16.59%
SMALL-CAP
CPRX	1.5B	348.4M	11.36%	-14.92%	24.59	4.38	81.69%	-7.29%
NVAX	656.6M	1.0B	-22.00%	-67.89%	-1.2	0.63	-43.15%	58.48%
INO	100.5M	6.4M	-	-79.23%	-0.61	15.6	-44.11%	50.48%
IBIO	39.5M	-	376.67%	112.17%	-0.61	-	-	-29.23%
CRBP	23.3M	-	25.24%	3980.68%	-0.49	-	-	-13.74%

United Therapeutics Corp News

Latest updates

Nasdaq • 08 Dec 2023 • 08:43 pm • 66 minutes ago

Notable Friday Option Activity: UTHR, CZR, RIVN

Yahoo Finance • 08 Dec 2023 • 02:05 pm • 7 hours ago

Insider Sell Alert: EVP & GENERAL COUNSEL Paul Mahon Sells ...

Knox Daily • 23 Nov 2023 • 08:00 am • 15 days ago

Insider Selling: MAHON PAUL A, United Therapeutics Corp [UTHR ...

Yahoo Finance • 01 Nov 2023 • 07:00 am • 37 days ago

United Therapeutics Corp (UTHR) Reports 18% YoY Revenue ...

The Business Journals • 01 Nov 2023 • 07:00 am • 37 days ago

Silver Spring's United Therapeutics betting big on organ ...

Morningstar • 30 Oct 2023 • 07:00 am • 39 days ago

Miromatrix Medical stock soars after it agrees to be bought by United ...

The Business Journals • 30 Oct 2023 • 07:00 am • 39 days ago

United Therapeutics to buy Miromatrix Medical - Washington ...

BNN Bloomberg • 10 Oct 2023 • 04:31 pm • 59 days ago

These three biotech stocks are undervalued: Wedbush analyst

Yahoo Finance • 08 Sep 2023 • 07:00 am • 3 months ago

EVP & GENERAL COUNSEL Paul Mahon Sells 6000 Shares of ...

The Business Journals • 16 May 2023 • 07:00 am • 6 months ago

United Therapeutics' Revivicor advancing Virginia manufacturing ...

TheStreet • 09 Mar 2023 • 08:00 am • 9 months ago

The 10 Best Biotech Stocks to Buy Now

Marketscreener.com • 22 Feb 2023 • 08:00 am • 9 months ago

United Therapeutics: Q4 Earnings Snapshot -February 22, 2023 at ...

StockNews.com • 21 Feb 2023 • 02:08 pm • 9 months ago

AMGN: 3 Biotech Stocks to Buy in 2023 That Could Help Set You up ...

Markets Insider • 07 Feb 2023 • 08:00 am • 10 months ago

Want To Copy 'Master Trader' Nancy Pelosi's Investments? There's ...

The Business Journals • 02 Nov 2022 • 07:00 am • 13 months ago

United Therapeutics posts record revenue, homes in on ambitious ...

Financials for United Therapeutics Corp

Income Statement (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	2.2%	609	597	507	492	516	467	462	415	445	447	379	385	380	362	356	311	402	374	363	381	413
Costs and Expenses	-0.2%	282	283	223	316	202	265	174	245	216	224	444	320	159	222	190	248	218	152	1,019	250	263
S&GA Expenses	-1.8%	128	130	87.00	-	98.00	142	79.00	-	109	113	-	-	-	-	-	-	-	-	-	66.00	-
R&D Expenses	-4.8%	85.00	89.00	83.00	94.00	66.00	94.00	69.00	83.00	79.00	74.00	304	126	69.00	90.00	73.00	114	86.00	86.00	897	139	101
EBITDA Margin	-100.0%	-	0.58*	0.52*	0.53*	0.53*	0.49*	0.53*	0.39*	0.38*	0.41*	0.38*	0.48*	0.48*	0.44*	0.52*	-0.05*	-	-	-	-	-
Interest Expenses	5.4%	16.00	15.00	14.00	12.00	9.00	6.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	8.00	10.00	12.00	12.00	10.00	4.00	4.00
Income Taxes	10.8%	84.00	76.00	51.00	47.00	73.00	35.00	69.00	28.00	42.00	44.00	4.00	16.00	48.00	27.00	34.00	16.00	35.00	45.00	-156	27.00	34.00
Earnings Before Taxes	5.0%	352	335	292	179	313	151	309	141	204	217	33.00	114	219	134	172	68.00	167	250	-650	92.00	140
EBT Margin	-100.0%	-	0.53*	0.47*	0.49*	0.49*	0.45*	0.49*	0.35*	0.34*	0.37*	0.33*	0.43*	0.42*	0.38*	0.46*	-0.11*	-	-	-	-	-
Net Income	3.2%	268	259	241	132	239	116	240	112	163	173	28.00	99.00	171	107	138	53.00	132	205	-494	65.00	107
Net Income Margin	-100.0%	-	0.41*	0.37*	0.38*	0.38*	0.35*	0.39*	0.28*	0.28*	0.30*	0.27*	0.35*	0.33*	0.30*	0.37*	-0.07*	-	-	-	-	-
Free Cashflow	-100.0%	-	62.00	334	89.00	190	110	275	104	162	132	79.00	114	235	146	202	78.00	-	-	-	-	-

Balance Sheet
(In Millions)

Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	5.1%	7,024	6,681	6,346	6,045	5,782	5,543	5,360	5,169	5,049	4,845	4,641	4,615	4,411	4,219	4,026	3,913	4,000	3,899	3,727	3,401	3,412
Current Assets	7.6%	3,459	3,213	3,193	3,380	3,056	2,684	2,587	2,324	2,386	2,318	2,014	2,167	1,868	1,894	1,846	1,865	1,933	2,140	1,943	1,768	1,609
Cash Equivalents	3.8%	1,108	1,067	1,164	961	967	795	813	895	909	942	832	739	670	685	875	738	720	881	791	669	656
Inventory	1.0%	104	103	103	102	91.00	90.00	88.00	94.00	97.00	90.00	92.00	87.00	88.00	90.00	92.00	93.00	94.00	97.00	96.00	101	101
Net PPE	5.7%	992	939	897	862	841	791	784	781	727	716	714	732	736	744	739	739	678	709	701	700	665
Liabilities	3.2%	1,312	1,270	1,223	1,248	1,219	1,225	1,184	1,210	1,219	1,205	1,196	1,220	1,128	1,126	1,077	1,133	1,284	1,332	1,389	593	700
Current Liabilities	100.9%	744	370	325	343	316	332	293	305	320	311	302	323	259	255	207	463	470	464	270	277	372
Shareholder's Equity	5.6%	5,712	5,411	5,123	4,797	4,562	4,318	4,176	3,959	3,830	3,640	3,445	3,395	3,283	3,094	2,949	2,780	2,716	2,558	2,319	2,789	2,693
Retained Earnings	4.8%	5,810	5,542	5,283	5,042	4,910	4,671	4,555	4,315	4,203	4,040	3,868	3,839	3,740	3,569	3,462	3,325	3,273	3,140	2,935	3,435	3,370
Additional Paid-In Capital	1.1%	2,524	2,498	2,457	2,388	2,315	2,292	2,254	2,245	2,226	2,197	2,173	2,149	2,126	2,105	2,068	2,048	2,026	2,002	1,968	1,940	1,924
Shares Outstanding	0.1%	47.00	47.00	47.00	46.00	46.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00	44.00

Cashflow (Last 12 Months)
(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	225.7%	346	106	375	128	259	127	289	175	186	148	90.00	126	251	164	215	103	185	133	-627	85.00	238
Share Based Compensation	52.9%	21.00	14.00	-12.40	65.00	-2.40	66.00	-21.10	45.00	25.00	29.00	40.00	94.00	-12.50	52.00	31.00	30.00	24.00	-37.20	29.00	3.00	51.00
Cashflow From Investing	-37.9%	-313	-227	-221	-189	-94.00	-169	-359	-195	-235	-48.90	-6.30	-63.80	-271	-375	-27.60	66.00	-298	-42.60	-60.30	-72.20	-329
Cashflow From Financing	-69.2%	8.00	25.00	49.00	56.00	7.00	24.00	-11.00	8.00	17.00	11.00	10.00	6.00	6.00	22.00	-50.20	-150	-48.30	0.00	809	0.00	2.00

UTHR Income Statement

2023-09-30

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Total revenues	$ 609.4	$ 516.0	$ 1,712.8	$ 1,444.8
Operating expenses:
Cost of sales	70.1	37.2	186.5	92.8
Research and development	84.7	66.1	256.6	229.0
Selling, general, and administrative	127.6	98.4	344.9	318.9
Total operating expenses	282.4	201.7	788.0	640.7
Operating income	327.0	314.3	924.8	804.1
Interest income	45.3	13.3	111.7	24.4
Interest expense	(15.6)	(9.2)	(44.2)	(20.1)
Other expense, net	(4.9)	(5.9)	(13.4)	(34.9)
Impairment of investment in privately-held company	0.0	0.0	0.0	(1.7)
Total other income (expense), net	24.8	(1.8)	54.1	(32.3)
Income before income taxes	351.8	312.5	978.9	771.8
Income tax expense	(84.2)	(73.2)	(211.2)	(176.6)
Net income	$ 267.6	$ 239.3	$ 767.7	$ 595.2
Net income per common share:
Basic (in dollars per share)	$ 5.71	$ 5.26	$ 16.44	$ 13.14
Diluted (in dollars per share)	$ 5.38	$ 4.91	$ 15.48	$ 12.35
Weighted average number of common shares outstanding:
Basic (in shares)	46.9	45.5	46.7	45.3
Diluted (in shares)	49.7	48.7	49.6	48.2

UTHR Balance Sheet

2023-09-30

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,107.7	$ 961.2
Marketable investments	1,767.8	1,877.5
Accounts receivable, no allowance for 2023 and 2022	258.6	220.4
Inventories, net	104.3	102.0
Other current assets	220.5	219.2
Total current assets	3,458.9	3,380.3
Marketable investments	2,060.8	1,316.2
Goodwill and other intangible assets, net	44.4	44.5
Property, plant, and equipment, net	992.2	861.5
Deferred tax assets, net	325.6	327.7
Other non-current assets	141.7	114.3
Total assets	7,023.6	6,044.5
Current liabilities:
Accounts payable and accrued expenses	333.4	229.9
Line of credit (current)	300.0	0.0
Share tracking awards plan	40.6	80.8
Other current liabilities	70.1	32.5
Total current liabilities	744.1	343.2
Line of credit (non-current)	500.0	800.0
Other non-current liabilities	67.4	104.6
Total liabilities	1,311.5	1,247.8
Commitments and contingencies
Stockholders’ equity:
Preferred stock, par value $.01, 10,000,000 shares authorized, no shares issued	0.0	0.0
Common stock, par value $.01, 245,000,000 shares authorized, 73,600,427 and 72,651,280 shares issued, and 46,981,211 and 46,032,064 shares outstanding as of September 30, 2023 and December 31, 2022, respectively	0.7	0.7
Additional paid-in capital	2,524.3	2,388.4
Accumulated other comprehensive loss	(43.7)	(55.5)
Treasury stock, 26,619,216 shares as of September 30, 2023 and December 31, 2022	(2,579.2)	(2,579.2)
Retained earnings	5,810.0	5,042.3
Total stockholders’ equity	5,712.1	4,796.7
Total liabilities and stockholders’ equity	$ 7,023.6	$ 6,044.5

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

CEO	Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
WEBSITE	www.unither.com
EMPLOYEES	985

United Therapeutics Corp Frequently Asked Questions

What is the ticker symbol for United Therapeutics Corp? What does UTHR stand for in stocks?

UTHR is the stock ticker symbol of United Therapeutics Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of United Therapeutics Corp (UTHR)?

As of Thu Dec 07 2023, market cap of United Therapeutics Corp is 11.37 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UTHR stock?

You can check UTHR's fair value in chart. The fair value of United Therapeutics Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of United Therapeutics Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for UTHR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is United Therapeutics Corp a good stock to buy?

The fair value guage provides a quick view whether UTHR is over valued or under valued. Whether United Therapeutics Corp is cheap or expensive depends on the assumptions which impact United Therapeutics Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UTHR.

What is United Therapeutics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, UTHR's PE ratio (Price to Earnings) is 12.64 and Price to Sales (PS) ratio is 5.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UTHR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on United Therapeutics Corp's stock?

In the past 10 years, United Therapeutics Corp has provided 0.103 (multiply by 100 for percentage) rate of return.

Market Summary

UTHR Alerts

UTHR Stock Price

UTHR RSI Chart

UTHR Alerts

UTHR Valuation

UTHR Price/Sales (Trailing)

UTHR Profitability

UTHR Fundamentals

UTHR Revenue

UTHR Earnings

Price Action

52 Week Range

How does UTHR drawdown profile look like?

UTHR Financial Health

UTHR Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for UTHR

Which funds bought or sold UTHR recently?

Latest Funds Activity

Schedule 13G FIlings of United Therapeutics Corp

Recent SEC filings of United Therapeutics Corp

UTHR Fair Value

Peers (Alternatives to United Therapeutics Corp)

United Therapeutics Corp News

Financials for United Therapeutics Corp

Income Statement (Last 12 Months).css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Balance Sheet(In Millions)

Cashflow (Last 12 Months)(In Millions)

UTHR Income Statement

UTHR Balance Sheet

About United Therapeutics Corp

United Therapeutics Corp Frequently Asked Questions

What is the ticker symbol for United Therapeutics Corp? What does UTHR stand for in stocks?

What is the market capital of United Therapeutics Corp (UTHR)?

What is the fair value of UTHR stock?

Is United Therapeutics Corp a good stock to buy?

What is United Therapeutics Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

What is 5 year return on United Therapeutics Corp's stock?

Income Statement (Last 12 Months)
(In Millions)

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)